Real-World Safety of Ixekizumab: A Disproportionality Analysis Using the FDA Adverse Event Reporting System and the VigiAccess Databases

The study analyzed the safety of ixekizumab using the FDA adverse event reporting system and VigiAccess databases, confirming several known adverse events (AEs) and identifying some unexpected ones. These findings offer preliminary safety insights to help clinicians use ixekizumab safely in practice. However, the study notes that results from spontaneous adverse event reporting systems are primarily hypothesis-generating and may be limited by issues such as underreporting, variable reporting quality, and confounding factors.